Cardinal Health news

While the company shows strong earnings growth expectations (14.51% EPS increase YoY) and revenue growth (4.6% YoY), the stock received a Hold rating (Zacks Rank #3) with no recent estimate revisions. The stock trades at a premium valuation (Forward P/E 17.99 vs. industry 16.97) and declined 1.64% in the latest session, offsetting positive fundamentals.

Despite a Strong Buy-equivalent average brokerage recommendation (1.39), the article advises caution. The Zacks Rank #3 (Hold) rating and unchanged consensus earnings estimate of $12.55 suggest the stock is expected to perform in line with the broader market rather than outperform. The article emphasizes that broker recommendations are often biased and unreliable, making the neutral Zacks Rank a more trustworthy indicator.

While facing significant IRA-related revenue headwinds (~500 basis points), management expects no adverse profit impact due to compensation preservation strategies and strong distribution agreements. Stock has outperformed industry YTD (+13.2% vs 5%), but carries a Hold rating with forward P/E above industry average.

Strong earnings beat (20.3% above consensus), significant year-over-year EPS growth (40% Q4, 37% full-year), raised FY27 guidance with 13-15% projected growth, improved margins, and outperformance versus S&P 500 over the past month.

Company is successfully integrating technology across operations, achieving operational improvements (99% fill rate, best on-time departures), and investing $700M in future growth. Stock up 17.5% YTD with Value Score of A, though currently rated Hold with forward P/E of 19.2X.

Generic volume growth exceeded planning assumptions, brand-to-generic conversions are driving profitability, and Pharma segment profit is expected to grow 8-11% in fiscal 2027. Stock has gained 19.4% year-to-date and carries a Value Score of A.

While the CFO's stock sale could signal profit-taking after a 57% gain, the company's strong financial performance (40% Q4 EPS growth), positive forward guidance (13-15% growth), substantial share repurchase program ($1B+), and management's statement that 'plans and priorities remain unchanged' suggest confidence in fundamentals. The insider sale appears routine portfolio management rather than a bearish signal.

While the stock has performed well with a 57% one-year return and the company maintains a strong market position ($55B market cap, $254.2B TTM revenue), the Medical segment—run by the selling executive—is described as 'still being fixed' with declining Q4 revenue (-2%), weak profit margins, and uncertain fiscal 2027 projections. The significant insider selling by a segment leader suggests concerns about near-term segment performance despite overall company strength.

The Pharma segment led by Weitzman showed strong fundamentals with 6% revenue growth and 21% profit growth in Q4. Specialty business grew over 25% in fiscal 2026. Management guidance for fiscal 2027 projects 3-5% segment revenue growth and 8-11% profit growth. The insider's decision to retain the majority of her stake after receiving performance units suggests confidence in the company's prospects.

The insider sale by the CIO is a modest negative signal, but the company's strong operational metrics (record service levels, $254.2B TTM revenue, $55B market cap) and significant technology investments provide offsetting positive factors. However, the guidance for lower adjusted free cash flow in fiscal 2027 despite higher capex spending raises questions about cash generation efficiency, warranting a neutral stance for long-term investors.

The company approved an increase to its quarterly dividend, demonstrating financial strength, confidence in future cash flows, and commitment to returning capital to shareholders. Dividend increases are generally viewed positively by investors as they signal management confidence and provide enhanced shareholder value.

While the company beat on EPS and raised full-year guidance, the stock declined 8.23% due to revenue missing consensus estimates ($60.94B vs. $61.70B expected) and flat performance in the Global Medical Products segment. The revenue miss appears to have outweighed positive guidance revisions in market sentiment.

Mentioned as one of three major U.S. wholesale distributors for AbbVie's domestic pharmaceutical sales; no specific sentiment expressed.

Mentioned only as the largest individual holding in NUMV at 2.34% of portfolio assets with no performance commentary or analysis provided.

Facing significant regulatory pressure from IRA with an estimated 500-basis-point Pharma revenue headwind, but management expects little to no profit impact due to protective service compensation and distribution agreements. Company appears positioned to absorb revenue pressure without margin deterioration.

Cardinal Health is mentioned as one of three major pharmaceutical distributors for AbbVie, representing a concentration risk. No independent analysis provided.

One of three major wholesalers accounting for 77% of Amgen's gross revenues, representing customer concentration risk.

Mentioned as a major pharmaceutical wholesaler/distributor for AbbVie products. No specific analysis provided regarding the company itself.

Referenced as another major pharmaceutical distributor for industry comparison purposes. No specific performance metrics or sentiment drivers mentioned in the article.

Strong fiscal 2026 close with $4.9B cash and $5.0B adjusted free cash flow, significant share repurchase activity of $1.4B, and increased repurchase authorization of $5.0B indicate robust financial position and commitment to shareholder returns.

Identified as a major player in the gauze bandage rolls market, which is experiencing steady growth with a 4.97% CAGR through 2035.

Listed as a significant competitor in the surgical masks market, positioned to benefit from consistent demand in healthcare settings and institutional supply chains.

Listed as a key player with distribution channel exposure through retail and online pharmacies, benefiting from the shift toward e-commerce and subscription models.

Fell 6.6% on soft quarterly print

Healthcare distributor positioned to benefit from increased radiopharmaceutical production and distribution expansion.

Featured as a key player in the robotic pharmacy market experiencing sustained growth, with opportunities in integrated solutions and service models.

Cardinal Health's logistics and distribution capabilities in the biopharmaceutical sector align with market growth drivers, particularly in distribution management and specialized handling.

Strong Q2 fiscal 2026 results with 18.6% revenue growth and EPS beat, 29% segment profit increase in Pharma & Specialty Solutions, raised full-year guidance, 39 consecutive years of dividend increases (Dividend Aristocrat status), and solid 5-year EPS growth of 13%.

Listed as a prominent participant in the medical device cleaning market, positioned to benefit from expanding healthcare infrastructure and rising demand for reprocessing solutions.